CRH Medical (NYSEAMERICAN:CRHM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “CRH Medical Corporation offers products and services to physicians for the treatment of gastrointestinal diseases primarily in the United States. The company provides the CRH O’Regan System, a single use, disposable and hemorrhoid banding technology for treating hemorrhoid grades I – IV. It distributes the CRH O’Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians. The company utilizes Web-based platform to connect doctors with patients as well as educating its install base of physicians. It also offers anesthesia services. CRH Medical Corporation is headquartered in Vancouver, Canada. “

How to Become a New Pot Stock Millionaire

CRHM stock opened at $2.70 on Wednesday. The firm has a market capitalization of $229.48, a PE ratio of 30.00 and a beta of 1.14. CRH Medical has a 52 week low of $1.46 and a 52 week high of $9.25.

Several large investors have recently made changes to their positions in CRHM. Vanguard Group Inc. purchased a new stake in shares of CRH Medical during the 2nd quarter valued at about $150,000. Mawer Investment Management Ltd. raised its holdings in shares of CRH Medical by 25.7% during the 3rd quarter. Mawer Investment Management Ltd. now owns 5,963,519 shares of the company’s stock valued at $15,542,000 after buying an additional 1,221,028 shares during the period. TD Asset Management Inc. raised its holdings in shares of CRH Medical by 65.3% during the 3rd quarter. TD Asset Management Inc. now owns 111,054 shares of the company’s stock valued at $289,000 after buying an additional 43,851 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of CRH Medical by 69.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 410,100 shares of the company’s stock valued at $964,000 after buying an additional 167,600 shares during the period. Finally, Stifel Financial Corp raised its holdings in shares of CRH Medical by 7.7% during the 3rd quarter. Stifel Financial Corp now owns 1,665,839 shares of the company’s stock valued at $4,332,000 after buying an additional 119,685 shares during the period.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2018/03/23/crh-medical-crhm-downgraded-by-zacks-investment-research-to-hold.html.

About CRH Medical

CRH Medical Corporation is a Canada-based healthcare products and services company. The Company focused on providing physicians with services and products for the treatment of gastrointestinal diseases. The Company also provides anesthesiology services to gastroenterologists in the United States through its subsidiaries.

Get a free copy of the Zacks research report on CRH Medical (CRHM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for CRH Medical (NYSEAMERICAN:CRHM)

Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.